Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totaling 11,793 shares, a decline of 97.2% from the April 30th total of 423,802 shares. Based on an average daily volume of 637,751 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

Chugai Pharmaceutical stock opened at $24.63 on Thursday. The company’s 50 day simple moving average is $26.42 and its 200-day simple moving average is $27.37. The company has a market capitalization of $81.07 billion, a price-to-earnings ratio of 27.37 and a beta of 0.63. Chugai Pharmaceutical has a 1 year low of $19.50 and a 1 year high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, April 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The business had revenue of $2.05 billion for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.